No Photo Available

Last Update

2017-01-09T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong David Verbraska?

Mr. David Verbraska

Vice President, Worldwide Policy and Public Affairs

Pfizer Inc

Direct Phone: (212) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Pfizer Inc

235 East 42Nd Street

New York, New York 10017

United States

Company Description

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care p ... more

Find other employees at this company (87,167)

Background Information

Employment History

Director of Corporate Communications

Cardinal Health , Inc.

General Manager, Corporate Communication

Delta Air Lines Inc.

Attorney and Lobbyist

Wilson Elser Moskowitz Edelman & Dicker LLP

Vice President

Worldwide Policy

Web References (26 Total References)


PR Summit - The Organization for Public Relations Leaders

www.prexecutives.org [cached]

Pfizer, David Verbraska, VP of Worldwide Policy & Public Affair


PR Best Practices Roundtable

www.pr-bestpracticesroundtable.com [cached]

Pfizer, David Verbraska, VP Worldwide Public Affair


Pharma Exec Blog » Events

blog.pharmexec.com [cached]

Panel moderator David Verbraska, Vice President for Regulatory Policy and Intelligence at Pfizer, noted the FDA stood at an “inflection pointâ€� in transitioning from simply engaging with patient groups to demonstrating how patient needs and outcomes rest at the center of drug review, based on clear metrics understood by all. As FDA tries to work out the finer points of the law, Pfizer relies on a simple metric in advancing the patient perspective. “Our goal is to innovate in bringing new therapies to patients that significantly improve their lives. We leave it to each patient to define what ‘significantly’ means, based on their own unique experience â€" it could be in helping to establish the right endpoints in a trial or shaping a post-marketing approval study that tracks safety and side-effect profiles.â€�

Panel moderator David Verbraska, Vice President for Regulatory Policy and Intelligence at Pfizer.
Panel moderator David Verbraska, Vice President for Regulatory Policy and Intelligence at Pfizer.
At the FDA, however, engagement with the patient is still more of an experiment, with highly variable expectations coming from each side â€" and industry is often caught in the middle. “Patient groups will say they desire more contact, or that things are not moving fast enough at the FDA for them. We then have to ask what level of involvement do you want, and to what end?â€� No one yet has a definitive response to these questions.â€� Instead of having to constantly reframe the discussion, Verbraska says what the industry needs is a clearly articulated pathway to collaborate with patient groups in informing and shaping decisions on market authorizations from the FDA.
The panel â€" which included, in addition to Verbraska, Andrew Emmett, Managing Director for Scientific and Regulatory Affairs at BIO; Marc Boutin, Chief Operating Officer of the National Health Council, and Kimberly McCleary, Director of Strategic Initiatives at Faster Cures â€" suggested a number of improvements to the “Voice of the Patientâ€� process, as follows:


Representing the other side of the ...

www.genengnews.com [cached]

Representing the other side of the coin, David Verbraska, Pfizer's vp, regulatory policy, said, "Should FDA choose to mandate public disclosure of investigator financial information, Pfizer recommends that the agency not require listing of specific payments or dollar amounts.


test_6

www.ismpp.org [cached]

David Verbraska, IFPMA Regulatory Policy and Technical Standards Committee member Vice President, Worldwide Regulatory Policy and Intelligence, Pfizer

Similar Profiles

Other People with this Name

Other people with the name Verbraska

Joseph Verbraska
Steelcase Inc.

Lisa Verbraska
State University of New York

Lesli Verbraska
Fort Bend County Schools

Michael Verbraska
DHS

Amanda Verbraska
East Carolina University

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory